Literature DB >> 33541472

Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study.

Angela Henderson1, Deborah Kinnear1, Michael Fleming1, Bethany Stanley1, Nicola Greenlaw1, Genevieve Young-Southward1, Jill P Pell1, Sally-Ann Cooper1.   

Abstract

BACKGROUND: Psychotropics are overprescribed for adults with intellectual disabilities; there are few studies in children and young people. AIMS: To investigate antipsychotic and antidepressant prescribing in children and young people with and without intellectual disabilities, and prescribing trends.
METHOD: Scotland's annual Pupil Census, which identifies pupils with and without intellectual disabilities, was record-linked to the Prescribing Information System. Antidepressant and antipsychotic data were extracted. Logistic regression was used to analyse prescribing between 2010 and 2013.
RESULTS: Of the 704 297 pupils, 16 142 (2.29%) had a record of intellectual disabilities. Antipsychotic and antidepressant use increased over time, and was higher in older pupils; antipsychotic use was higher in boys, and antidepressant use was higher in girls. Overall, antipsychotics were prescribed to 281 (1.74%) pupils with intellectual disabilities and 802 (0.12%) without (adjusted odds ratio 16.85, 95% CI 15.29-18.56). The higher use among those with intellectual disabilities fell each year (adjusted odds ratio 20.19 in 2010 v. 14.24 in 2013). Overall, 191 (1.18%) pupils with intellectual disabilities and 4561 (0.66%) without were prescribed antidepressants (adjusted odds ratio 2.28, 95% CI 2.03-2.56). The difference decreased each year (adjusted odds ratio 3.10 in 2010 v. 2.02 in 2013).
CONCLUSIONS: Significantly more pupils with intellectual disabilities are prescribed antipsychotics and antidepressants than are other pupils. Prescribing overall increased over time, but less so for pupils with intellectual disabilities; either they are not receiving the same treatment advances as other pupils, or possible overprescribing in the past is changing. More longitudinal data are required.

Entities:  

Keywords:  Intellectual disabilities; antidepressants; antipsychotics; children; young people

Mesh:

Substances:

Year:  2021        PMID: 33541472     DOI: 10.1192/bjp.2020.232

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  1 in total

Review 1.  Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review.

Authors:  Neasa Kelly; Andrew Kilmartin; Kevin Lannon; Caren Lee; Rory McLoughlin; Lara Mulvanny; Omnyiah Mohamed; Mairead Treacy; Karen Rossi; Juliette O'Connell
Journal:  Eur J Clin Pharmacol       Date:  2022-08-31       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.